2019 ASCO Annual Meeting Highlights for the Advanced Practitioner: Prostate Cancer

摘要

An interim analysis of the international, randomized phase III ENZAMET trial found that 80% of men with metastatic hormone-sensitive prostate cancer who received the non-steroidal antiandrogen agent enzalutamide along with standard-of-care treatment were alive after 3 years, compared with 72% of men who received other nonsteroidal antiandro-gens along with standard treatment. These findings were presented during the 2019 ASCO Annual Meeting Plenary Session by Sweeney et al. (Abstract LBA2).